Vigil Neuroscience (NASDAQ:VIGL) Rating Increased to Strong-Buy at William Blair

William Blair upgraded shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) to a strong-buy rating in a research note issued to investors on Thursday, April 24th,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Wedbush lowered their price objective on Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday, March 14th. Guggenheim reissued a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, HC Wainwright reduced their target price on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a report on Friday, March 14th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $16.25.

Vigil Neuroscience Stock Performance

Shares of VIGL traded up $0.30 on Thursday, reaching $2.40. The stock had a trading volume of 198,140 shares, compared to its average volume of 798,039. The firm has a market capitalization of $117.85 million, a price-to-earnings ratio of -1.16 and a beta of 1.94. The company has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $2.38. Vigil Neuroscience has a 12-month low of $1.31 and a 12-month high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). On average, analysts expect that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Large investors have recently modified their holdings of the company. abrdn plc grew its holdings in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after acquiring an additional 293,461 shares during the period. Geode Capital Management LLC grew its holdings in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock worth $769,000 after acquiring an additional 66,712 shares during the period. Blair William & Co. IL bought a new stake in shares of Vigil Neuroscience in the fourth quarter worth $551,000. Northern Trust Corp grew its holdings in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after acquiring an additional 14,572 shares during the period. Finally, Woodline Partners LP grew its holdings in shares of Vigil Neuroscience by 239.1% in the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company's stock worth $831,000 after acquiring an additional 344,614 shares during the period. Institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.